SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    SEED Innovations ‘Delighted’ as Investee Little Green Pharma Wins Italian Government Supply Tender

    By

    Investee Company Update: Little Green Pharma Ltd

    SEED Innovations Ltd, the AIM quoted company investing in fast growing and industry leading businesses with a focus on the medical cannabis, health and wellness space, is pleased to note an announcement by its portfolio company, Little Green Pharma Ltd (‘LGP’).

    SEED owns a holding of 7,324,796 ordinary shares in LGP representing 3.1% of LGP’s issued share capital.

    Alfredo Pascual, VP of Investment Analysis of SEED, commented: “We are delighted by our investee company Little Green Pharma performance in the most recent Italian government supply tender. This represents an entry into the Italian medical cannabis market, one of the largest in Europe, and positions them well for future possibly larger supply application processes in the country. LGP passing the strict government qualification requirements is another reflection of the high quality of medical cannabis flower that LGP are producing from its Danish facility.

    “This is also an endorsement of LGP’s European strategy, and with a growing presence on the continent we hope to hear more from LGP as they progress product pathways into other countries, including Greece and Poland where progress has been announced in recent months.”

    The announcement by Little Green Pharma Ltd is set out below without material changes or adjustments:

    LGP WINS ITALIAN TENDER

    Highlights:

    ·    LGP awarded Government tender for medicinal cannabis flower from its Danish Facility into Italy

    ·    Italian Government tenders the sole route into Italian flower market, with tender quality standards some of the highest globally and LGP one of only two suppliers to bid for tender

    ·    Award builds on Company’s growing European market momentum as LGP joins small group of international cannabis producers qualified to supply cannabis flower medicines into Italy

    ·    Tender award grants LGP access to Italian market with 60 million population and Total Addressable Market of A$10 billion

    Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce the award of an Italian Government tender to deliver a shipment of EU GMP medicinal cannabis flower from its Danish Facility into Italy.

    The shipment value of ~€200,000 is not material, however with the award LGP has joined a small group of international cannabis producers qualified to supply cannabis flower medicines into Italy, positioning LGP strongly for future upcoming Italian Government tenders. Italy has a population of 60 million people and a Total Addressable Market estimated at ~A$10 billion.

    Italian Government tenders impose some of the highest GMP product quality standards globally, with LGP one of only two suppliers bidding for the tender and with only Aurora having been successful in the past. The shipment will be of historic inventory acquired as part of LGP’s purchase of its Danish Facility from Canopy Growth.

    The Italian award builds on LGP’s growing momentum in European and UK markets, with LGP now having supplied products into Germany, France, the UK and Denmark as it also continues to progress product registration pathways into Greece and Poland.

    10 June 2026 · Berlin Sales end May 29

    European Cannabis
    Insights Summit

    From €216

    200+ industry leaders. Exclusive German market data. A half-day briefing for B2B operators in Europe's most important emerging cannabis market.

    BusinessCann

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free